1. Inicio
  2. Publicaciones
  3. How bilastine is used to treat allergic rhinitis and urticaria in children

How bilastine is used to treat allergic rhinitis and urticaria in children

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Rodríguez del Río P
  • Ballester Asensio E
  • Tortajada-Girbés M

Abstract

Management guidelines for allergic rhinitis and urticaria recommend oral second-generation antihistamines as first-line treatment. The efficacy and safety of bilastine, the newest nonsedating second-generation antihistamine, are well established in adolescents/adults with these allergic conditions. The bilastine development program for pediatric use (2-<12 years) followed EMA-authorized processes. Pharmacokinetic/pharmacodynamic simulation and modeling and a pharmacokinetic study were conducted to identify and confirm the pediatric dose (10 mg/day). A Phase III, multicenter, double-blind, randomized, placebo-controlled, parallel-group study was performed to confirm the safety of bilastine 10 mg/day in children. In this article, evidence is reviewed for use of bilastine in children with allergic rhinoconjunctivitis or urticaria. Several cases are presented which demonstrate its role in routine clinical practice.

Datos de la publicación

ISSN/ISSNe:
1750-743X, 1750-7448

IMMUNOTHERAPY  FUTURE MEDICINE LTD

Tipo:
Article
Páginas:
77-89

Citas Recibidas en Web of Science: 3

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • allergic rhinitis; allergic rhinoconjunctivitis; bilastine; children; pediatric formulations; pediatric safety; second-generation antihistamines; urticaria

Compartir